Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
COLLEGIUM PHARMACEUTICAL, INC
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-5.4% vs price
Base Case (Median)
26.4% vs price
Bull Case (75th pct.)
94.4% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $54.35 | 146.8% | High (40%) |
| PE Comparable | $27.84 | 26.4% | Medium (25%) |
| Growth Trajectory DCF | $42.80 | 94.4% | Medium (20%) |
| Graham Number | $16.10 | -26.9% | Medium (40%) |
| Earnings Power Value | $20.82 | -5.4% | Medium (50%) |
Based on 5 out of 7 methods, COLL appears fairly valued at the current price of $22.02. The base case fair value of $27.84 implies 26.4% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.